This page shows the latest UniQure news and features for those working in and with pharma, biotech and healthcare.
CSL licensed the exclusive global rights to Hemgenix from gene therapy company uniQure in May 2021 and is now solely responsible for the further development, registration and commercialisation of the therapy.
CSL licensed the exclusive global rights to Hemgenix from gene therapy company uniQure in May 2021 and is now solely responsible for the further development, registration and commercialisation of the therapy.
Matt Kapusta, chief executive officer of uniQure, also said the approval represented a “major milestone in the field of genomic medicine and ushers in a new treatment paradigm for patients living ... CSL licensed the exclusive global rights to Hemgenix
In a statement, uniQure said that the patient diagnosed with HCC had ‘multiple risk factors’ associated with this type of cancer. ... UniQure added that all patients in its haemophilia clinical programme have abdominal ultrasounds performed one year
Athough, analysts at Jefferies have previously suggested that with a number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.
number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.
More from news
Approximately 13 fully matching, plus 25 partially matching documents found.
Gene therapy failures. The industry and Europe’s healthcare systems are wary of that magic one million threshold, thanks to the failure of the first ever gene therapy, UniQure’s Glybera. ... The success or failure of Bluebird will be closely watched
success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... The EMA approved the world’s first ever
Unfortunate message. Some of these thorny problems were encapsulated in uniQure’s recent decision not to seek an extension to its five-year European marketing authorisation - which expires in October - for
BMS will also take a 4.9% equity stake in uniQure which will cost around $32m, with another 5% ownership scheduled before the end of the year (at 10% premium). ... UniQure also stands to receive research, development and regulatory milestones, including
32, 700. uniQure NV/ Bristol-Myers Squibb. R&D collaboration plus equity investment.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Meyer joins the biotech from uniQure B.V where he was chief medical officer and has held several similar roles for Cardoz, Symphogen, Zymenex and Novo Nordisk.
Based in the Netherlands and the US, uniQure has appointed Matthew Kapusta as its chief executive officer. ... This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals.
Will serve as gene therapy specialist's chief commercial officer. Gene therapy company uniQure has appointed Hans Christian Rohde to serve as its new chief commercial officer. ... In his new role at Netherlands-based uniQure he will be tasked with
More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.
There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
Not just another healthcare communications agency. We are a collection of award-winning industry experts focusing on bringing the very best...